Wire · opportunities
Datroway Shows Encouraging Results for Triple-Negative Breast Cancer That Has Spread ...
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
Datopotamab deruxtecan (Datroway) showed promising results controlling brain metastases in patients with metastatic triple-negative breast cancer who cannot receive immunotherapy, demonstrating longer central nervous system progression-free survival and higher brain tumor shrinkage compared to chemotherapy in a small exploratory trial.
This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.
◆ ◆ The Wire takeaway
You can explore Datroway as a treatment option for metastatic triple-negative breast cancer patients with brain metastases who cannot take immunotherapy, but be cautious given the small study size and exploratory nature of the data.
◆ Coverage
1 source · 26 Oct 2026
◆ Related on Wire
◆ Topics